In recent years, with the continuous improvement of high-throughput sequencing and bioinformatics analysis technology, the feasibility and effectiveness of individualized and precise tumor treatment is becoming more and more effective, and the concept of precision therapy is gradually gaining attention, and the comprehensive treatment of liver cancer has gradually left the previous mode of empirical treatment to move in the direction of evidence-based and precision. The US NIH/NCI department has designed the MATCH Clinical Oncology Precision Therapy Program to expand the innovation of clinical cancer trials based on personalized cancer therapy and to promote the development of precision cancer therapy. Medical Prognosis, a Danish company (listed on NASDAQ, USA) is currently engaged in a full strategic collaboration with our center to introduce its patented technology in the field of oncology precision therapy to the Chinese medical market in a comprehensive manner. The company has decided to set up a testing laboratory in Beijing as soon as possible to validate the predictive and screening technologies of several major anti-hepatocellular carcinoma drugs (sorafenib, doxorubicin, cisplatin, gemcitabine, capecitabine and oxaliplatin) in hospital patients with hepatocellular carcinoma in a superior population, with the goal of The goal is to eventually build a database of Chinese liver cancer patients for precision treatment through a series of prospective clinical trials. In addition, the hospital is investigating the use of circulating tumor cell screening technology, which has been rapidly developed in recent years, to obtain genomic data of tumors more quickly and non-invasively, so that the results of precision medicine can bring clinical benefits to more patients.